February 15, 2022
Source: Trends Cancer. 2022 Feb 15;S2405-8033(22)00017-6. doi: 10.1016/j.trecan.2022.01.010.
Authors: Jitka Fucikova, Lenka Palova-Jelinkova, Vanessa Klapp, Peter Holicek, Tereza Lanickova, Lenka Kasikova, Jana Drozenova, David Cibula, Beatriz Álvarez-Abril, Elena García-Martínez, Radek Spisek, Lorenzo Galluzzi.
At odds with other solid tumors, epithelial ovarian cancer (EOC) is poorly sensitive to immune checkpoint inhibitors (ICIs), largely reflecting active immunosuppression despite CD8+ T cell infiltration at baseline. Accumulating evidence indicates that both conventional chemotherapeutics and targeted anticancer agents commonly used in the clinical management of EOC not only mediate a cytostatic and cytotoxic activity against malignant cells, but also drive therapeutically relevant immunostimulatory or immunosuppressive effects. Here, we discuss such an immunomodulatory activity, with a specific focus on molecular and cellular pathways that can be harnessed to develop superior combinatorial regimens for clinical EOC care.